Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base

Highlights

• The 2026 JAMA Internal Medicine cluster randomized clinical trial by Verma and colleagues provides the strongest evidence to date that structured palliative care for end-stage liver disease (ESLD) can be effectively delivered by hepatologists trained in primary palliative care.
• Across 19 US centers and 935 patients with decompensated cirrhosis or hepatocellular carcinoma, quality of life improved significantly in both the hepatologist-led and specialist palliative care arms; hepatologist-delivered care met a prespecified noninferiority criterion.
• Secondary outcomes reinforce the signal: symptom burden and depression improved in both groups, while patient satisfaction improved more in the hepatologist arm, suggesting that embedded liver clinicians may offer practical advantages in continuity and acceptability.
• These findings align with the broader serious-illness palliative care literature, which shows consistent benefits for symptom control, communication, and patient-centered outcomes, and they help address a major implementation bottleneck in hepatology: limited access to specialty palliative care.

Background

End-stage liver disease occupies a uniquely difficult clinical space. Patients with decompensated cirrhosis or advanced hepatocellular carcinoma often experience heavy symptom burden, repeated hospitalizations, functional decline, nutritional impairment, frailty, depression, caregiver strain, and highly uncertain trajectories. Yet palliative care has historically been underused in hepatology, in part because liver disease does not follow a linear terminal pathway, in part because transplantation can remain a conditional rescue option, and in part because palliative care is too often misconstrued as synonymous with end-of-life care alone.

The unmet need is substantial. Individuals with ESLD commonly experience pain, pruritus, fatigue, muscle cramps, sleep disturbance, ascites-related discomfort, dyspnea, encephalopathy-related distress, anxiety, depressive symptoms, and decisional conflict regarding hospitalization, intensive interventions, transplant candidacy, and goals of care. These burdens coexist with unpredictable reversibility: a patient may deteriorate rapidly after variceal bleeding, spontaneous bacterial peritonitis, or hepatorenal syndrome, but may also partially recover after procedures or disease-modifying therapy. This uncertainty has made prognostication difficult and has often delayed symptom-focused, communication-centered care.

In oncology and other serious illnesses, the evidence base for palliative care is mature. Randomized trials and meta-analyses have shown that palliative care can improve quality of life, symptom burden, mood, and sometimes healthcare utilization. However, liver disease has lagged behind, with most earlier ESLD evidence being observational, single-center, or feasibility-focused. That gap is precisely why the 2026 trial by Verma et al is clinically important: it does not merely ask whether palliative care helps ESLD patients; it asks who can deliver it effectively in real-world hepatology practice.

Key Content

Why palliative care matters specifically in ESLD

Several features make ESLD especially suitable for integrated palliative care:

• High multidimensional symptom burden: beyond pain, liver patients experience ascites discomfort, pruritus, cramps, fatigue, anorexia, sleep fragmentation, cognitive changes, and existential distress.
• Uncertain illness trajectory: acute decompensations alternate with partial recovery, complicating both prognostic discussions and timing of referral.
• Transplant-related ambiguity: palliative care may be mistakenly deferred because clinicians or families equate it with abandonment of transplant intent, despite the fact that palliative care is fully compatible with ongoing disease-directed treatment.
• Care fragmentation: hepatology, oncology, transplant surgery, hospital medicine, interventional radiology, and primary care may all participate, increasing the need for communication and goal alignment.

Mechanistically, palliative care may improve outcomes in ESLD through several pathways: systematic symptom assessment, anticipatory management of complications, earlier clarification of goals and preferences, caregiver support, better illness understanding, and more coherent care plans across hospital and outpatient settings. A liver specialist trained in primary palliative care may be particularly effective when symptom interventions must be tightly integrated with cirrhosis management, transplant candidacy discussions, and the pharmacologic constraints imposed by hepatic dysfunction.

Evidence before 2026: strong rationale, limited liver-specific randomized data

Before the Verma trial, the case for palliative care in liver disease rested on three main pillars.

First, the broader serious-illness literature was already persuasive. Temel and colleagues’ landmark randomized trial in metastatic non-small-cell lung cancer demonstrated that early outpatient palliative care improved quality of life and mood while also influencing end-of-life care patterns. Subsequent meta-analytic work, including the JAMA systematic review by Kavalieratos et al, showed that palliative care is associated with better patient quality of life and symptom outcomes across serious illnesses. These studies did not solve the ESLD-specific question, but they established the biologic and clinical plausibility of benefit.

Second, hepatology literature consistently documented unmet palliative needs. Observational studies and reviews in cirrhosis and transplant populations described burdensome symptoms, poor prognostic understanding, delayed advance care planning, low hospice utilization, and frequent aggressive end-of-life care. They also identified cultural and structural barriers: clinician discomfort with goals-of-care discussions, difficulty distinguishing supportive care from hospice, and the perception that transplantation and palliative care are competing rather than complementary frameworks.

Third, professional guidance gradually moved toward integration. Guidance from oncology normalized early palliative care as a component of high-quality specialty care rather than a referral reserved for the final weeks of life. Hepatology reviews and practice discussions increasingly recommended embedding symptom assessment, communication, and advance care planning into routine cirrhosis care. Still, until 2026, one key question remained unresolved: if specialist palliative care capacity is scarce, can hepatologists themselves deliver a structured intervention with similar effectiveness?

The Verma et al 2026 trial: design and methodological significance

Verma and colleagues addressed that implementation-critical question in a comparative effectiveness, cluster randomized clinical trial conducted across 19 US medical centers. The study randomized centers, not individual patients, to one of two delivery models:

• Hepatologist group: palliative care delivered by hepatologists trained in primary palliative care.
• Consultative group: palliative care delivered by conventional palliative care specialists.

This design deserves emphasis. Cluster randomization is particularly sensible for service-delivery interventions because it reduces contamination within sites, reflects how clinics actually operate, and evaluates implementation at the systems level. The intervention itself consisted of four palliative care visits over three months using a structured checklist, promoting fidelity while preserving pragmatic relevance.

Eligibility focused on adults with decompensated cirrhosis or hepatocellular carcinoma, a life expectancy of at least six months, no scheduled or prior liver transplantation, and no recent palliative care exposure. These choices enriched the sample for patients likely to benefit from longitudinal supportive care while avoiding confounding from active transplant pathways or duplicate palliative services.

The primary endpoint was change in quality of life at three months measured by the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) total score. FACT-Hep is a clinically appropriate instrument here because it captures broad health-related quality of life relevant to hepatobiliary disease rather than only narrow symptom metrics. The trial was framed as testing superiority or, prespecifically, noninferiority of hepatologist-delivered palliative care versus specialist palliative care. That noninferiority framework is highly pragmatic: if trained hepatologists can achieve similar patient-centered outcomes, scalability improves dramatically.

Main findings: noninferior quality-of-life improvement with hepatologist-delivered care

The trial enrolled 935 patients, with a mean age of 63.0 years; 29% were female, 14% identified as Hispanic ethnicity, 15% as Black, and 79% as White. This is a large cohort by hepatology supportive care standards and enhances confidence in generalizability across US tertiary settings.

The central result was straightforward and clinically meaningful. From baseline to three months, quality of life improved significantly in both groups:

• Hepatologist arm: adjusted mean improvement 8.01 points (95% CI, 5.38 to 10.65; P<.001).
• Consultative specialist arm: adjusted mean improvement 7.02 points (95% CI, 4.34 to 9.71; P<.001).

Superiority of hepatologist-led care was not demonstrated. However, the prespecified noninferiority analysis was positive, with an adjusted mean difference of 0.98 points (95% CI, -2.86 to 4.83; P=.01 for noninferiority). In other words, hepatologist-delivered palliative care was not worse than specialist-delivered palliative care by the trial’s predefined margin and produced a very similar magnitude of quality-of-life improvement.

For implementation science, this is arguably the most important message of the paper. Specialist palliative care remains a limited resource in many liver practices, especially outside academic centers. A finding of noninferiority supports a tiered model in which hepatologists provide core palliative care competencies, reserving specialist referral for more complex symptoms, refractory psychosocial distress, conflict, or advanced decision support needs.

Secondary outcomes: broad benefit in symptom burden and mood, with higher satisfaction in the hepatologist arm

The secondary outcomes complement the primary finding. Symptom burden improved in both groups, with adjusted mean changes of -7.52 (95% CI, -9.89 to -5.15) in the hepatologist group and -5.31 (95% CI, -7.60 to -3.03) in the consultative group. Depression also improved in both groups, with adjusted mean changes of -1.18 (95% CI, -1.78 to -0.57) and -0.90 (95% CI, -1.49 to -0.31), respectively. There were no significant between-group differences for these endpoints.

These data suggest that the essential therapeutic ingredients of the intervention were present in both models: repeated contact, structured assessment, attention to symptoms and distress, and ongoing communication. That is consistent with the broader palliative care literature, which has repeatedly shown that systematic supportive care, rather than discipline-specific identity alone, drives benefit.

One secondary finding did distinguish the groups: patient satisfaction improved more in the hepatologist arm than in the specialist palliative care arm, with adjusted mean changes of 3.37 (95% CI, 2.24 to 4.49) versus 0.91 (95% CI, -0.15 to 1.96), respectively (P=.002). Several interpretations are plausible:

• Patients may perceive discussions as more coherent when symptom management and liver-specific treatment planning occur within the same clinical relationship.
• Hepatologists may be able to contextualize supportive care recommendations more precisely around ascites management, encephalopathy, portal hypertensive complications, and transplant-related uncertainties.
• Embedded delivery may reduce the stigma or psychological threshold associated with referral to a separate palliative care service.

Mortality at three months was similar between groups, which is unsurprising. The intervention was not primarily intended to alter short-term survival, and palliative care trials more commonly demonstrate gains in patient-centered outcomes than mortality effects.

What this trial changes in practice

The study meaningfully shifts the discussion from whether palliative care should be used in ESLD to how it can be operationalized.

A practical model emerging from these data is a stepped palliative care framework:

• Primary palliative care by hepatologists: routine symptom screening, values clarification, caregiver assessment, advance care planning, and management of common distressing symptoms.
• Specialist palliative care consultation: refractory pain or pruritus, complex depression/anxiety, conflict around treatment decisions, severe caregiver strain, existential distress, or needs related to hospice transition.

This model is attractive because it is scalable, aligns with workforce realities, and preserves specialist palliative care for patients with the highest complexity. The structured checklist used in the trial is also noteworthy: in implementation terms, checklists make skill transfer possible, improve consistency, and facilitate quality assurance across centers.

Comparison with the broader palliative care evidence base

The Verma trial is directionally consistent with the broader serious-illness evidence. Randomized studies outside liver disease, especially in cancer, have shown that repeated, outpatient-oriented palliative interventions improve quality of life and mood. Meta-analytic evidence has reinforced these effects, though magnitudes vary depending on timing, intervention intensity, and outcome instruments.

What distinguishes the ESLD trial is not merely replication of benefit but demonstration that specialty-trained hepatologists can deliver it. In oncology, integrated care models increasingly place some palliative competencies within routine disease-specific practice. The 2026 ESLD trial extends that logic to hepatology and offers empirical support rather than aspiration alone.

It also sharpens an important conceptual distinction: specialist palliative care expertise remains essential, but universal specialist-only delivery is not necessary for every supportive care need. For health systems, that is a major finding.

Strengths of the trial

The study has several notable strengths:

• Large multicenter sample: 935 participants across 19 centers exceeds the scale of most prior liver supportive care studies.
• Pragmatic relevance: real-world clinicians delivered a structured intervention in routine US practice environments.
• Cluster randomization: appropriate for minimizing contamination and studying care-delivery models.
• Clinically meaningful endpoint: quality of life is the right primary outcome for a palliative intervention in ESLD.
• Prespecified noninferiority framework: directly addresses the workforce and scalability question facing hepatology.

Limitations and points for cautious interpretation

Despite its importance, the trial should not be overinterpreted.

First, follow-up was limited to three months for the primary assessment. That is appropriate for early efficacy but leaves open questions about durability, hospitalization patterns, hospice utilization, caregiver outcomes, and late-stage decision quality.

Second, the intervention required trained hepatologists and a structured protocol. The results therefore support trained hepatologist-delivered palliative care, not informal or unstructured supportive conversations without competency development.

Third, patients had a life expectancy of at least six months and were not actively proceeding to transplant. Whether the same model performs similarly among patients on transplant waiting lists, those with rapidly progressive acute-on-chronic liver failure, or those with severe recurrent encephalopathy needs further study.

Fourth, the trial compared two active interventions, not palliative care versus usual care. That is a strength for comparative effectiveness but means the study does not quantify the incremental effect of receiving structured palliative care versus the baseline standard many ESLD patients currently receive.

Fifth, generalizability to low-resource settings, community hospitals without palliative infrastructure, and non-US healthcare systems remains uncertain.

Expert Commentary

The most important translational implication of this trial is that hepatology should now move from referral-dependent palliative care to competency-based integrated palliative care.

From a workforce standpoint, the result is timely. Demand for palliative care already exceeds specialist supply in many settings. If hepatologists can be trained to deliver core palliative interventions using standardized tools, then the reach of supportive care for cirrhosis and hepatocellular carcinoma can expand substantially without waiting for major workforce growth.

From a mechanistic standpoint, the stronger satisfaction signal in the hepatologist arm is especially interesting. In ESLD, patients often need highly nuanced explanations about competing priorities: diuretic intensification versus renal risk, opioid caution in encephalopathy-prone patients, nutritional goals despite sarcopenia and ascites, or transplant candidacy despite frailty. A hepatologist may be uniquely positioned to integrate these tradeoffs while maintaining disease-focused credibility. That may enhance trust and reduce the sense that palliative care represents a separate or terminal pathway.

Still, the trial should not be used to diminish the role of specialist palliative care. Rather, it argues for a layered model. Hepatologists can manage foundational palliative tasks, but specialist teams remain crucial for advanced symptom pharmacology, complex communication, family conflict mediation, bereavement support, and hospice transitions. This division mirrors how many fields increasingly think about palliative care delivery: primary palliative care for all, specialist palliative care for complexity.

Several research priorities follow directly from these findings:

• Longer-term outcomes: effects on hospitalization, intensive care use, hospice timing, caregiver burden, and healthcare costs.
• Training science: what curriculum, duration, supervision, and fidelity checks are needed for hepatologists to achieve reproducible outcomes?
• Subgroup effects: differential benefit in decompensated cirrhosis versus hepatocellular carcinoma, high-MELD populations, recurrent encephalopathy, and transplant-listed patients.
• Equity analyses: whether integrated palliative care reduces disparities in communication, symptom management, and end-of-life care among racially and ethnically diverse populations.
• Caregiver outcomes: ESLD imposes heavy caregiver burden; future trials should formally capture caregiver distress and preparedness.

For clinicians, the immediate lesson is practical: palliative care in liver disease should no longer be viewed as an optional adjunct reserved for the final phase of illness. It is a quality-of-care domain that can be taught, standardized, measured, and embedded into hepatology practice.

Conclusion

The 2026 cluster randomized trial by Verma and colleagues is a landmark study for hepatology supportive care. In patients with decompensated cirrhosis or hepatocellular carcinoma, structured palliative care improved quality of life whether delivered by trained hepatologists or by specialist palliative care clinicians, and hepatologist-led delivery met prespecified noninferiority criteria. Symptom burden and depression improved in both groups, while patient satisfaction improved more with hepatologist-delivered care.

In the context of earlier serious-illness palliative care research, these findings provide a missing implementation bridge for ESLD. The study supports a scalable, integrated model in which hepatologists provide primary palliative care using structured training and protocols, with specialist palliative care reserved for complex needs. For a field long marked by unmet symptom burden, prognostic uncertainty, and underuse of supportive care, that is a clinically important advance.

The next phase of research should define how best to train clinicians, identify which patients need specialist escalation, measure longer-term and caregiver outcomes, and ensure equitable delivery across diverse practice settings. But one conclusion is already clear: palliative care is not peripheral to advanced liver disease care. It is central to it.

References

• Verma M, Navarro V, Kosinski A, Taddei T, Kalman R, Barritt AS 4th, Jakab S, Serper M, Orman E, Balakrishnan M, Rakoski M, Rockey D, Hunt K, Cabrera R, Aytaman A, John B, Baffy G, Nathan R, Tapper E, Roytman M, McGuire B, Hoppmann N, Woodrell C, Bakitas M, Yue Y, Reeve B, Lin L, Tantala R, Volk M. Palliative Care Intervention for Patients With End-Stage Liver Disease: A Cluster Randomized Clinical Trial. JAMA Internal Medicine. 2026;186(6):677-686. PMID: 41973444.
• Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer. New England Journal of Medicine. 2010;363(8):733-742.
• Kavalieratos D, Corbelli J, Zhang D, Dionne-Odom JN, Ernecoff NC, Hanmer J, Hoydich ZP, Ikejiani DZ, Klein-Fedyshin M, Zimmermann C, Morton SC, Arnold RM, Heller L, Schenker Y. Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-analysis. JAMA. 2016;316(20):2104-2114.
• Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, Firn JI, Paice JA, Peppercorn JM, Phillips T, Stovall EL, Zimmermann C, Smith TJ. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 2017;35(1):96-112.
• Haun MW, Estel S, Rücker G, Friederich HC, Villalobos M, Thomas M, Hartmann M. Early palliative care for adults with advanced cancer. Cochrane Database of Systematic Reviews. 2017;6:CD011129.